Department of Pediatrics, Division of Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Chest. 2021 Feb;159(2):507-516. doi: 10.1016/j.chest.2020.09.247. Epub 2020 Sep 28.
Eosinophilia with pulmonary involvement is characterized by the presence of peripheral blood eosinophilia, typically ≥500 cells/mm, by pulmonary symptoms and physical examination findings that are nonspecific, and by radiographic evidence of pulmonary disease and is further supported by histopathologic evidence of tissue eosinophilia in a lung or pleura biopsy specimen and/or increased eosinophils in BAL fluid, usually >10%. Considering that there are a variety of underlying causes of eosinophilia with pulmonary manifestations and overlapping clinical, laboratory, and radiologic features, it is essential to approach the evaluation of eosinophilia with pulmonary findings systematically. In this review, we will describe a case presentation and discuss the differential diagnosis, a directed approach to the diagnostic evaluation and supporting literature, the current treatment strategies for pulmonary eosinophilia syndromes, and the levels of evidence underlying the recommendations, where available. Overall, optimal management of eosinophilic lung disease presentations are directed at the underlying cause when identifiable, and the urgency of treatment may be guided by the presence of severe end-organ involvement or life-threatening complications. When an underlying cause is not easily attributable, management of eosinophilia with pulmonary involvement largely relies on eosinophil-directed interventions, for which biologic therapies are increasingly being used.
伴有肺部受累的嗜酸性粒细胞增多症的特征是外周血嗜酸性粒细胞增多,通常≥500 个/ mm,伴有肺部症状和非特异性体检结果,以及肺部疾病的影像学证据,并进一步支持肺或胸膜活检标本中组织嗜酸性粒细胞增多和/或 BAL 液中嗜酸性粒细胞增多的组织病理学证据,通常>10%。鉴于有多种潜在原因可导致伴有肺部表现的嗜酸性粒细胞增多症,且其临床表现、实验室和影像学特征存在重叠,因此必须系统地评估伴有肺部发现的嗜酸性粒细胞增多症。在本次综述中,我们将描述一个病例报告,并讨论鉴别诊断、针对诊断评估的针对性方法以及支持性文献、目前的肺部嗜酸性粒细胞增多症综合征治疗策略,以及在有可用证据的情况下,推荐建议的证据水平。总体而言,当可识别潜在病因时,针对潜在病因的治疗是嗜酸粒细胞性肺部疾病表现的最佳管理方式,治疗的紧迫性可能取决于严重终末器官受累或危及生命的并发症的存在。当无法轻易归因于潜在病因时,伴有肺部受累的嗜酸性粒细胞增多症的管理主要依赖于针对嗜酸性粒细胞的干预措施,越来越多地使用生物疗法。